Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
Summary
-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend C...
Description
-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend C...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source